Skip to search formSkip to main contentSkip to account menu

Dipeptidyl Peptidase-4 Inhibitor

Known as: DPP-4 Inhibitor 
Any inhibitor of the proline-specific serine protease dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. DPP-4 inhibitors bind to DPP-4 and… 
National Institutes of Health

Related topics

Related topics

3 relations
Dipeptidyl Peptidase 4 Inhibitor [EPC]Dipeptidyl Peptidase 4 Inhibitors [MoA]Dipeptidyl-Peptidase IV Inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
Renal fibrosis is considered to be the final common outcome of chronic kidney disease. Dipeptidyl peptidase-4 (DPP-4) inhibitors… 
Review
2018
Review
2018
Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes
Background: Dipeptidyl peptidase-4 (DPP-4) inhibitor and pioglitazone combination therapy have been widely used for patients with… 
2016
2016
Cardiovascular safety of glucose‐lowering agents as add‐on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register
To investigate the relative safety of various glucose‐lowering agents as add‐on medication to metformin in type 2 diabetes in an… 
2015
2015
The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose.
2013
2013
Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs
The pharmacokinetic disposition of anagliptin, an orally active and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor was… 
2013
2013
The DPP-4 inhibitor MK0626 and exercise protect islet function in early pre-diabetic kkay mice
Highly Cited
2011
Highly Cited
2011
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase‐4 inhibitor, and pioglitazone on glycemic control and measures of β‐cell function in patients with type 2 diabetes
Aim/hypothesis:  To assess the safety and efficacy of initial combination therapy with sitagliptin and pioglitazone compared with… 
2010
2010
Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5mg–10mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in…
Background and ObjectivesLinagliptin (BI 1356) is a highly specific inhibitor of dipeptidyl peptidase (DPP)-4, which is currently… 
Highly Cited
2009
Highly Cited
2009
Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects
ABSTRACT Objective: Linagliptin (BI 1356) is a novel, orally available inhibitor of dipeptidyl peptidase-4 (DPP-4). Linagliptin… 
Review
2009
Review
2009
Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Boehringer Ingelheim Corp is developing the novel, xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor linagliptin for the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)